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In a multicentre, double-blind, randomized, parallel study, 426 asthmatic children aged 5-15 years old received 
salmeterol 50,~g b.i.d. or placebo b.i.d. via the Diskhaler@. All patients had access to inhaled salbutamol to be used 
on an ‘as required’ (p.r.n.) basis for symptomatic relief. The study design comprised a 2-week baseline, a 1Zmonth 
treatment period incorporating a 2-week ‘off treatment’ after 6 months, and a 2-week follow-up period at the end of 
the trial. At the end of 12 months of treatment with salmeterol, the adjusted change from baseline for morning and 
evening peak expiratory flow rate (PEF) was 56 and 47 1 min ~ ‘, respectively, and this was significantly greater than 
placebo (PcO.01; WO.05). Exacerbation rates did not differ between groups and results were not dependent upon 
concurrent inhaled steroid use. Neither treatment caused a change of z 1 doubling dose in PC,,/PD,, either during 
or on stopping treatment. 
Treatment with regular salmeterol 5Opg b.i.d. over a 12-month treatment period provides a significant, rapid and 
well-maintained improvement in lung function without increasing bronchial reactivity or asthma exacerbation rates 
compared to p.r.n. salbutamol. 
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Introduction 
Short-acting inhaled P-adrenoceptor agonists are recom- 
mended in international and national guidelines for the 
effective relief of acute bronchoconstriction in asthmatic 
patients (1,2), and are widely recognized as having an 
essential role in asthma treatment (3,4). In recent years, the 
role of regular &agonist therapy for the treatment of 
asthma has come under much debate, with some publi- 
cations (5,6) suggesting that regular inhalation of a short- 
acting ,&-agonist is associated with a deterioration in 
asthma control. At issue is the concern that provision of 
relatively sustained bronchodilation and control of symp- 
toms may potentially lead to deterioration of the underlying 
disease state, and hence contribute to an increase in the 
asthma morbidity and mortality rate. 
Salmeterol xinafoate is a long-acting inhaled &agonist 
which has been developed to be taken on a regular basis 
to prevent asthma symptoms, in contrast to short-acting 
&agonists intended to be taken on an ‘as required’ basis 
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(p.r.n.) for relief of acute symptoms. The &agonist debate 
has aroused speculation on the safety of salmeterol as 
regular maintenance asthma treatment. 
Evidence from many comparative clinical trials in adults 
and children have confirmed that regular salmeterol treat- 
ment leads to a sustained improvement in lung function 
and better overall asthma control without increasing 
asthma exacerbation rate (16-18). In particular, data from 
adult studies have confirmed that patients receiving regular 
salmeterol compared to regular salbutamol or p.r.n. sal- 
butamol had improved lung function and symptom control 
(19), lower requirement for inhaled steroids (20) a lower 
incidence of asthma exacerbations (21) and improved 
asthma-specific quality of life (22). 
No long-term data in children assessing regular vs ‘as 
required’ inhaled p-agonist therapy has been published. The 
aim of this study was, therefore, to compare the safety and 
efficacy of regular salmeterol 50,~g b.i.d. vs salbutamol 
taken on a p.r.n. basis over a period of 12 months in mild to 
moderate asthmatic children. 
Methods 
PATIENTS 
Children eligible to take part in the study were aged 6-15 
years, had a documented history of reversible airways 
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obstruction and required inhaled &agonist for sympto- 
matic control. Additionally, during the 2-week run-in 
period, children were required to demonstrate an increase 
in FEV, or PEF of at least 15% after inhalation of 200 pug 
salbutamol or a diurnal variation in PEF of > 15% on the 
7 days prior to randomization, and an FEV, of ~90% 
predicted normal value or a current morning PEF of ~85% 
of their best ever documented value. Patients were not 
eligible if they had a requirement for more than 12OOpg 
salbutamol per day during the last 7 days of the run-in, had 
changed their asthma medication, had experienced a hospi- 
tal admission for asthma, had suffered a lower respiratory 
tract infection in the previous 4 weeks, required oral 
corticosteroid, anticholinergic or methylxanthine therapy at 
time of study entry or were currently receiving P-blocking 
agents. Other &agonist use apart from the study medica- 
tion was not permitted during the trial. Prior to the start of 
the study, children were required to demonstrate the correct 
use of the Diskhaler and peak flow meter. Bronchial 
challenge with methacholine was performed in a subset 
of participating centres. All patients were treated on an 
outpatient basis. 
STUDY AND DESIGN 
This was a randomized, double-blind, parallel-group, 
placebo-controlled study, performed in over 57 centres in 
11 countries. Each centre obtained ethical committee ap- 
proval and the study was performed in accordance with the 
Declaration of Helsinki 1964. Written consent for patient 
entry was obtained from all patients/guardians and, where 
appropriate, patients provided witnessed oral consent. 
Daily Assessments 
Peak expiratory flow was measured in triplicate, morning 
and evening, on a mini-Wright peak flow meter before 
taking study medication or using rescue salbutamol. The 
best of three manoeuvres was recorded in the daily record 
card (DRC), together with the daytime and night-time use 
of rescue salbutamol and presence or absence of asthma 
symptoms. 
Clinic Assessments 
Clinic visits were scheduled after randomization at 1, 3 and 
6 months, after a further 2-weeks ‘off-treatment’ period, at 
9 and 12 months and at the end of a 2-week follow-up 
period. Assessments of lung function (FEV, and PEF) and 
airway responsiveness to bronchial challenge with metha- 
choline (in selected centres) were made at all clinic visits 
after randomization, except at 1 and 9 months. Metha- 
choline challenges were performed approximately 12 h after 
study medication dosing. Investigators checked patients 
were taking their study medication by completion of the 
diary card question and from returned used study medica- 
tion. Patients recorded any adverse events experienced or 
changes in concurrent medication in the DRC. Asthma 
exacerbations were monitored and recorded as adverse 
events throughout the study. An asthma exacerbation was 
defined as any worsening of asthma requiring a change in 
prescribed therapy. Patients experiencing asthma exacer- 
bations were treated at the discretion of the participating 
physician, and were permitted to continue in the trial. 
Children entered a 2-week run-in period during which all 
pre-study bronchodilator therapy was replaced by inhaled 
salbutamol to use on a p.r.n. basis throughout the study. 
The placebo group can, therefore, effectively be considered 
as a p.r.n. salbutamol group. Children currently receiving 
inhaled glucocorticosteroids, sodium cromoglycate, nedo- 
cromil sodium or ketotifen were permitted to continue with 
this treatment into the study providing the medication dose 
remained constant wherever possible throughout the study 
period. If patients had an asthma exacerbation during the 
study, they were allowed to alter their concurrent asthma 
therapy at the investigator’s discretion. 
Patients who fulfilled the inclusion criteria were rand- 
omized to receive either salmeterol 5Opg b.i.d. or placebo 
b.i.d. via the Diskhaler for the next 12 months. After the 
first 6 months of study treatment, there was a 2-week 
‘off-treatment’ period to assess the effect of stopping study 
treatment on bronchial reactivity. Patients then resumed 
taking their study medication for a further 6 months. At the 
end of the trial, there was a 2-week follow-up period during 
which patients continued taking any permitted concurrent 
pre-trial asthma medication but did not continue with their 
study treatment. 
Analysis 
Analysis was performed on the total population rand- 
omized to treatment who took at least one dose of study 
medication (intent-to-treat population). This study was 
designed to have a power of over 90% to detect a mean 
difference between treatments of 12 1 min - ’ in PEF at a 5% 
significance level. The primary variable for comparing the 
cflicacy of treatments was change (from baseline) in mean 
morning PEF. Data from week 2 of the run-in period was 
defined as baseline for analysis. 
Analyses were performed over weeks 1-24 to reduce 
multiple testing, at the end of the 2-week ‘off-treatment’ 
period (weeks 24426), over monthly intervals in the second 
6-month treatment period and at the end of the follow-up 
period (weeks 52-54). 
For mean morning and evening PEF (expressed as abso- 
lute values), clinic visit FEV, and PEF, the changes from 
baseline were analysed using analysis of covariance 
(ANCOVA) with baseline value age and sex as covariates, 
and sex and country as factors. Mean values adjusted for 
these effects were calculated, and the significance of differ- 
ences between treatments and 95% confidence limits were 
MEASUREMENTS 
based on the ‘t’ distribution. A test for the interaction of 
treatment with each covariate was performed, and for PEF, 
A full clinical history was documented and a physical ex- an assessment was made on the consistency of the treatment 
amination including routine haematology and biochemistry effect across concurrent inhaled steroid use (as defined at 
was performed at the first clinic visit prior to randomization. randomization). 
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TABLE 1. Patient characteristics 
Placebo 
Salmeterol 
5Opg b.i.d. 
Number of patients 
Mean (SD) age (years) 
Range 
Sex 
Male 
Female 
Mean (SD) height (cm) 
Mean (SD) baseline FEV, (% predicted) 
Mean (SD) baseline clinic PEF (% predicted) 
206 220 
10 (2) 10 (2) 
5-15 5-15) 
123 (60%) 139 (63%) 
83 (40%) 81 (37%) 
140 (14) 142 (15) 
78 (14) 77 (15) 
85 (21) 84 (20) 
Patients using concurrent asthma medication at randomization: 
Inhaled corticosteroids 101 (49%) 122 (55%) 
Sodium cromoglycate 46 (22%) 51 (23%) 
Other 15 (7%) 7 (3%) 
The percentage of symptom-free nights and days and the 
percentage of nights and days with no rescue salbutamol 
were analysed using the Wilcoxon Rank Sum test, stratified 
by country grouping using the van-Elteren extension. 
The incidence of asthma exacerbation was investigated 
between the treatment groups using a Wilcoxon rank 
sum test for exacerbations occurring at any time during 
treatment or off-treatment. A further analysis was made 
stratifying by use of concurrent inhaled steroid. 
In selected centres PC,, and PD,, values were estimated 
by linear interpolation between the log,, concentrations or 
log,, cumulative doses enclosing a 20% reduction in FEV,. 
The doubling dose change (DD) in adjusted mean PC,, or 
PD,, was calculated as follows: 
DD=log,,(PC,, or PD,, at visit) - log,,(PC,, or PD,, at baseline) 
hhl2 
The DD was analysed by ANCOVA, adjusting for baseline, 
age, sex and country, and pairwise comparisons between 
the treatment groups were performed using the t-test. 
Use of concurrent anti-inflammatory steroid for patients 
undergoing challenge was assessed. 
Results 
Six hundred and twenty-seven patients were enrolled into 
the study, of which 426 were randomized to treatment (206 
to placebo, 220 to salmeterol 5Opg b.i.d.). Of all random- 
ized patients, 360 patients completed the study. After 
randomization b.i.d., 66 patients (29 in the placebo group, 
37 in the salmeterol group) withdrew for the following 
reasons: adverse events (14) non-compliance (26), failure 
to return (14) and other reasons (12). Demographic 
details and patient characteristics at randomization are 
shown in Table 1; both treatment groups were similar. At 
randomization, the concurrent use of inhaled corticoster- 
oids was 49% of patients in the placebo group compared 
with 55% in the salmeterol 5Opg b.i.d. group. Concurrent 
use of sodium cromoglycate was 22 and 23% for the groups, 
respectively. 
PEAK EXPIRATORY FLOW 
An immediate increase in mean morning and evening PEF 
was observed for patients receiving salmeterol 50,~~g b.i.d. 
within the first few days, immediately after commencing 
treatment, and is shown in Fig. 1. Over weeks l-24, patients 
receiving salmeterol 5Opg b.i.d. had an adjusted mean 
change above baseline in mean morning PEF of 34 1 min ~ ’ 
compared to 17 1 min - ’ for placebo [treatment difference 
17 1 mini ‘, 95% CI (10,24); P<O.OOl]. The improvement in 
mean morning PEF was maintained throughout the second 
6-month treatment period and was statistically significant 
at all analysis points relative to placebo (all P values 
~0.03) e.g. at weeks 33-36 and 49952, there was a treat- 
ment difference of 15 and 12 1 min - ’ in favour of the 
salmeterol 5Opg b.i.d. group [95% CI (7,24); P<O.OOl and 
95% CI (3,22); P=O.O09, respectively]. 
Similarly, over weeks l-24, patients receiving salmeterol 
5Opg b.i.d. showed an adjusted mean change of 25 1 min ~ ’ 
above baseline in mean evening PEF compared to 
12 1 min ~ ’ for placebo [treatment difference 13 1 min - ’ 
95% CI (6,19); P<O.OOl]. The adjusted mean change in 
predicted mean evening PEF was statistically significant in 
favour of salmeterol compared to placebo at analysis points 
for weeks 29-32, 33-36, 4144 and 49-52 in the second 
6-month treatment period (all P values ~0.05). 
The treatment difference between groups in PEF was not 
significant when patients came ‘off-treatment’ and stopped 
study medication for 2 weeks after the first 6-month treat- 
ment period and at follow-up. Analysis of PEF stratified by 
concurrent steroid use was not significant. 
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FIG. 1. Mean daily peak expiratory flow (PEF) (1 min ~ ‘) 
(a) morning (b) evening. -, salmeterol 50 ,~g b.i.d.; 
--, placebo b.i.d. 
SYMPTOMS 
At baseline, the median percentage of symptom-free days 
was high for patients in both treatment groups (86%), and 
although this improved in both groups during a 12-month 
treatment period, there was no significant statistical differ- 
ence between treatments. The median percentage of 
symptom-free nights at baseline for both groups was 100%. 
The salmeterol group showed a higher frequency distribu- 
tion of percentage of symptom-free nights compared to 
placebo, and this was statistically significant over weeks 
l-24 (P=O.OOS) and over weeks 29-32, 33-36 and 3740 of 
the trial (PcO.05). 
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USE OF RESCUE SALBUTAMOL 
The median percentage of days with no rescue salbutamol 
at baseline was 43% in the placebo group compared to 29% 
in the salmeterol group. The median percentage of days 
with no use of rescue salbutamol improved in both groups 
throughout the study to 90% over weeks 49-52 for both 
groups. The median percentage of nights with no rescue 
salbutamol at baseline was 71% for both treatment groups. 
Patients receiving salmeterol 5Opg b.i.d. showed a higher 
frequency distribution of percentage of nights with no 
rescue salbutamol use compared to the placebo group, and 
this was significant at all analysed time points during the 
12-month treatment period (PI 0.05). 
CLINIC ASSESSMENTS 
Clinic visit FEV, data (Table 2) showed a statistically 
significant treatment difference (PcO.05) in favour of the 
salmeterol 50 pug b.i.d. group compared to placebo at 12, 24 
and 52 weeks during treatment. 
METHACHOLINE CHALLENGE 
Change from baseline in methacholine PC,, or PD,, was 
expressed as doubling dose change, where each patient’s 
results are a change from their own baseline (Fig. 2). 
Numbers of patients undergoing methacholine challenge at 
12, 24 and 52 weeks were 155, 149 and 140, respectively. 
Patients treated with salmeterol 50 pg b.i.d. demonstrated 
an adjusted mean protective effect of approximately 0.7-0.8 
doubling doses of methacholine. This protective effect was 
reduced in the 2-week ‘off treatment’ period when study 
medication was stopped, but did not fall below baseline. 
Neither treatment caused a change of more than one 
doubling dose of methacholine. Of the 140 undergoing 
bronchial challenge at 12 months, 107 (76%) were using 
concurrent anti-inflammatory medication (this included 
inhaled corticosteroids, sodium cromoglycate and 
nedocromil sodium). Patients in the salmeterol 50,~g b.i.d. 
group receiving no concurrent anti-inflammatory medica- 
tion (n=20) demonstrated a decrease in bronchial reactivity 
over the 12-month treatment period, with no rebound effect 
on stopping treatment. These results are summarized in 
TABLE 2. Clinic visit FEV, 
Time 
(weeks) 
Placebo Salmeterol 50 pg b.i.d. 
Litres (% predicted) Litres (% predicted) 
Visit 2 0 1.68 (78) 1.76 (78) 
Visit 4 12 1.76 W) 1.92 (85) 
Visit 5 24 1.82 (85) 2.01 (88) 
Visit 6 (off treatment) 26 1.81 (84) 1.91 (83) 
Visit 8 (follow-up) 52 1.91 (89) 2.09 (91) 
Visit 9 54 1.95 (89) 1.99 m 
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FIG. 2. Adjusted means of PC,,/PD,, expressed as doubling doses of methacholine related to baseline. 0, salmeterol 50,~~g 
b.i.d.; 0, placebo. Number of patients undergoing challenge at 12, 24, 26, 52 and 54 weeks were 74, 64, 75, 70 and 68 for 
placebo, and 81, 85, 75, 70 and 59 for salmeterol, respectively. 
TABLE 3. Patients undergoing bronchial challenge and not 
taking concurrent anti-inflammatory medication 
Salmeterol 50 pg b.i.d. 
Weeks rl Doubling doses* 
12 20 0.52 
24 20 0.38 
26 18 0.29 
52 14 0.52 
54 11 0.84 
*Adjusted means of PC,,/PD,, expressed as doubling doses 
of methacholine related to baseline. 
Table 3). Due to low patient numbers, a statistical analysis 
was not applicable. 
ASTHMA EXACERBATIONS 
In the placebo group, 53% (109) of patients experienced an 
asthma exacerbation during the study treatment period 
(excluding the 2 week ‘off- treatment’ period and follow-up) 
compared to 62% (137) in the salmeterol50 pg b.i.d. group. 
Asthma exacerbation data at time intervals during the 
study are shown in Fig. 3. There was no statistically 
significant difference between the treatment groups in the 
number of patients with asthma exacerbations during the 
12-month treatment period (P=O.2). A further analysis 
stratifying by use of concurrent inhaled steroids was also 
not significant. 
SAFETY AND TOLERABILITY 
Of the 426 patients randomized to treatment, a total of 66 
patients (15%) withdrew from the study. Fourteen patients 
withdrew due to an adverse event: six in the placebo group 
and eight in the salmeterol group. Adverse events which led 
to withdrawal included asthma, headache, tremor and 
cough. 
The overall incidence of adverse events experienced dur- 
ing the first and second 6-month treatment periods was high 
but similar across treatment groups: 76-74% with placebo 
and 77-68% with salmeterol (incidences given for first- 
second 6-month treatment period). The most commonly 
reported adverse events with both treatments were asthma, 
exacerbations, upper respiratory tract infection, fever, sore 
throat, bronchitis, cough (all expected in a young atopic 
population) and headache (as shown in Table 4). 
Placebo and salmeterol 5Opg b.i.d. were both well toler- 
ated; the incidence of drug-related adverse events was 
1611% in the placebo group and 13-11% in the salmeterol 
group (incidences given for first-second 6-month treatment 
period). The pharmacologically predictable adverse events 
reported during treatment were headache, tremor and 
muscle cramp, and there was no evidence of a statistically 
significant difference between treatment groups in the 
incidence of these. 
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FIG. 3. Percentage of patients with at least one exacerbation at time intervals during the study treatment period. 
0, salmeterol SOpug b.i.d.; q , placebo. 
TABLE 4. Most commonly reported adverse events 
Weeks l-24 Weeks 2652 
Placebo Placebo 
(n=206) (n= 187) (n %6) 
W) (o/o) WI (‘i/o) 
Any adverse event 76 77 74 68 
Asthma 42 48 37 45 
URTI 23 28 23 19 
Headache 10 13 8 10 
Fever 11 10 9 5 
Sore throat 12 10 12 11 
Bronchitis 10 10 12 9 
Cough 12 9 9 8 
SM, salmeterol 5Opg b.i.d.; URTI, upper respiratory tract infection. 
Discussion 
Debate continues over the benefit of regular use of 
&agonists in the treatment of asthma, specifically with 
regard to the issues of asthma control, airway reactivity and 
tolerance (23-26). This study set out to address some of the 
concerns raised by the &agonist debate, by evaluating the 
efficacy and safety of regular treatment with salmeterol 
5Opg b.i.d. compared to p.r.n. salbutamol in asthmatic 
children over a 12-month period. 
Patients receiving salmeterol 50 pug b.i.d. had statistically 
significant better morning and evening PEF compared to 
those taking p.r.n. salbutamol, and this was maintained 
throughout the 12-month treatment period. The improve- 
ment was independent of concurrent inhaled steroid use. 
The placebo group also demonstrated a notable improve- 
ment in PEF from baseline over the 12-month treatment 
period. This may possibly have been an ‘in study’ effect 
resulting from closer compliance by patients with other 
permitted pre-existing medications that were being taken 
concurrently during the study. 
The median percentage of symptom-free days and nights 
at baseline was high for both groups, reflecting a mild to 
moderate asthmatic population of children. Patients in the 
salmeterol group showed a higher frequency distribution of 
percentage of symptom-free nights and a higher percentage 
of nights with no use of rescue salbutamol, which was 
significant compared to the p.r.n. salbutamol group. This 
is probably attributable to the effective long duration 
of bronchodilating action of salmeterol, and is a very 
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important finding as sleep disturbance is one of the main 
features of asthma. Improving nights without awakening 
would no doubt be of great benefit to the children. The fact 
that salmeterol did not affect daytime symptoms is perhaps 
surprising. In all adult studies, salmeterol was shown to 
have a positive effect in reducing daytime symptoms 
(16,17,20). In a recently published paper where children 
were required to be symptomatic on entry to the study, 
salmeterol 50,ug b.i.d. was shown to significantly improve 
the percentage of symptom-free days (30). The present 
study did not have a requirement for patients to be symp- 
tomatic on entry (median % symptom-free days at baseline 
was 86%) hence there was little room for improvement. If 
a more symptomatic population were selected, as in the 
studies by Russell et al. (30) and by Gotz et al. (31) it is 
presumed that salmeterol would be beneficial in controlling 
daytime symptoms. 
It has been cited that regular use of &-agonists may 
increase bronchial responsiveness either during or upon 
cessation of treatment @,I 1); however, results from recent 
studies have shown no evidence of a clinically deleterious 
effect on bronchial reactivity (12-1520). In this study, a 
protective effect of between 0.7-0.8 doubling doses of 
methacholine was observed in patients receiving salmeterol 
5Opg b.i.d. this protective effect was maintained through- 
out the 12-month treatment period with no evidence of 
rebound increase in bronchial hyper-responsiveness (BHR) 
on cessation of treatment. The protective effect observed in 
this study is in agreement with results from other studies 
(13,29) which measure the effect of methacholine challenge 
at least 12 h after dosing with salmeterol. 
Of the patients in this study undergoing methacholine 
challenge, approximately 76% were using concurrent anti- 
inflammatory medication (inhaled corticosteroids, sodium 
cromoglycate or nedocromil sodium). A similar protective 
effect to methacholine challenge was observed for those 
patients in the salmeterol 5Opg b.i.d. group not taking 
concurrent anti-inflammatory medication, suggesting that 
it is unlikely that the protective effect was attributable to 
use of anti-inflammatory medication. In addition, patients 
who were taking concurrent steroids were required to be 
using their maintenance treatment for at least 1 month 
prior to study entry, and the dose was to be kept constant 
throughout the study period where possible. 
The long-term safety data from this large multicentre 
study allows the critical evaluation of safety issues over the 
use of regular vs ‘as required’ &agonist therapy in children, 
for which there is currently limited published data. Asthma 
exacerbation rate provides an indication of the overall 
control of a patient’s asthma. If the regular use of &- 
agonists was leading to a worsening of asthma control as 
suggested (5,6), one may expect to see an increase in the 
frequency and/or rate of asthma exacerbations for the 
salmeterol group. However, there was no statistically 
significant difference between treatment groups in the 
number of patients experiencing an exacerbation of asthma 
during the 12-month treatment period. This effect was 
seen irrespective of whether patients were or were not using 
concurrent inhaled corticosteroids. The overall incidence 
of adverse events, although high, was similar between 
treatment groups. Asthma was the most commonly 
reported adverse event and there was no evidence of a 
statistically significant difference between treatment groups 
in this. 
In conclusion, asthmatic children receiving regular treat- 
ment with salmeterol 5Opg b.i.d. over a 12-month treat- 
ment period demonstrated a significant and maintained 
improvement in lung function compared to salbutamol 
p.r.n. Salmeterol treatment was also associated with a 
significant reduction in night-time symptoms and use of 
rescue bronchodilator at night. There was no evidence of 
increased BHR during treatment with salmeterol, or of a 
rebound increase in bronchial reactivity on stopping treat- 
ment. No deterioration in asthma control (as measured by 
exacerbation rates) as a result of taking regular long-term 
treatment with salmeterol 5Opg b.i.d. was identified. The 
data support the consensus view that regular treatment with 
salmeterol xinafoate 5Opg remains an appropriate, effi- 
cacious and safe maintenance treatment option for children 
with asthma. 
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